Intercept Pharmaceuticals (NASDAQ:ICPT) had its target price boosted by Citigroup from $106.00 to $140.00 in a note issued to investors on Thursday. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Citigroup‘s price target indicates a potential upside of 41.37% from the company’s current price.
Other research analysts also recently issued research reports about the company. JMP Securities increased their target price on Intercept Pharmaceuticals from $175.00 to $200.00 and gave the company an “in-line” rating in a report on Wednesday. Royal Bank of Canada increased their target price on Intercept Pharmaceuticals to $137.00 and gave the company a “sector perform” rating in a report on Wednesday. Oppenheimer upped their price target on Intercept Pharmaceuticals from $140.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday. Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, October 31st. Finally, Zacks Investment Research cut Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 12th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and fifteen have issued a buy rating to the company. Intercept Pharmaceuticals presently has an average rating of “Buy” and an average target price of $150.79.
ICPT stock opened at $99.03 on Thursday. Intercept Pharmaceuticals has a fifty-two week low of $58.03 and a fifty-two week high of $133.74. The company has a debt-to-equity ratio of 3.83, a quick ratio of 5.98 and a current ratio of 5.98. The stock has a market capitalization of $3.49 billion, a price-to-earnings ratio of -6.89 and a beta of 1.88.
In related news, insider David Shapiro sold 2,000 shares of the stock in a transaction dated Friday, February 15th. The stock was sold at an average price of $111.51, for a total transaction of $223,020.00. Following the completion of the sale, the insider now owns 42,543 shares in the company, valued at $4,743,969.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Christian Weyer sold 1,343 shares of the stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $113.78, for a total value of $152,806.54. Following the sale, the executive vice president now owns 17,162 shares of the company’s stock, valued at approximately $1,952,692.36. The disclosure for this sale can be found here. Insiders have sold 764,130 shares of company stock valued at $80,329,205 in the last quarter. 4.90% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC grew its position in shares of Intercept Pharmaceuticals by 3.6% during the fourth quarter. Squarepoint Ops LLC now owns 3,399 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 118 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Intercept Pharmaceuticals by 14.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,416 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 183 shares during the last quarter. LPL Financial LLC boosted its stake in Intercept Pharmaceuticals by 0.3% during the fourth quarter. LPL Financial LLC now owns 74,815 shares of the biopharmaceutical company’s stock valued at $7,541,000 after buying an additional 254 shares during the last quarter. Advisor Group Inc. boosted its stake in Intercept Pharmaceuticals by 63.5% during the fourth quarter. Advisor Group Inc. now owns 739 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 287 shares during the last quarter. Finally, Strs Ohio boosted its stake in Intercept Pharmaceuticals by 30.0% during the fourth quarter. Strs Ohio now owns 1,300 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 65.00% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.
See Also: Stop Order Uses For Individual Investors
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.